HalleCMooreMD

Oncology • Cleveland, OH

Physician

Join to view full profile

Dr. Moore is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Moore's full profile

Already have an account?

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 800-223-2273

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1996 - 1997
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1993 - 1996
Case Western Reserve University School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 2003 - Present
OH State Medical License 1999 - 2026
IL State Medical License 2002 - 2020
NY State Medical License 2003 - 2020
MI State Medical License 2002 - 2018
PA State Medical License 1996 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 3
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Start of enrollment: 2003 Nov 01
Active, not recruiting
Phase 3
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers Start of enrollment: 2008 Jul 01
Terminated
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity Start of enrollment: 2015 Oct 14
Completed
Not Applicable
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
ACTIVE_NOT_RECRUITING
PHASE3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral Guidelines.
Teodora Kuzmanovic, Maedeh Zoakei Nikoo, Sindhusha Veereballi, Ahmad Safdar, Sakthi S Prakash
Journal of the National Comprehensive Cancer Network. 2025-03-28
Clinical Behavior of Breast Cancer in YoungCarriers and Prediagnostic Awareness of GermlineStatus.
Matteo Lambertini, Eva Blondeaux, Loredana M Tomasello, Elisa Agostinetto, Anne-Sophie Hamy
Journal of Clinical Oncology. 2025-02-24
Covert Breast Cancer Metastasis to the Gastrointestinal Tract: Is Extra Vigilance Needed?
Sarah Wehbe, Stephen A Firkins, Jacob R Sweeney, Halle C F Moore, Carol Rouphael
ACG Case Reports Journal. 2025-01-01

Authored Content

Pondering the RxPONDER StudyDecember 2020

Press Mentions

VIDEO: OlympiA Trial Shows Olaparib’s Benefits for Patients with BRCA Mutations ‘Persist’December 24th, 2024
VIDEO: Risk-Reducing Surgeries Result in ‘Fewer Breast Cancer Events’ for BRCA CarriersDecember 23rd, 2024
Merck-AstraZeneca Breast Cancer Drug Reduces Risk of Death by 28% in Patients Diagnosed Early, Clinical Trial ShowsDecember 21st, 2024
Join now to see all